Lantern Pharma Inc.(LTRN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
LTRN Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Lantern Pharma Inc. (LTRN), a Healthcare sector company. LTRN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of LTRN by reported 13-F value include Empery Asset Management, CM Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LTRN trades on the Nasdaq exchange and files with the SEC under CIK 1763950. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LTRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lantern Pharma Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-7.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+17.6% YoYOperating Income
+19.1% YoYEPS (Diluted)
+18.7% YoYTotal Assets
-56.8% YoYOp. Cash Flow
+12.0% YoYFree Cash Flow
+12.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-17.1M +17.6% | $-20.8M -30.2% | $-16.0M -11.9% | $-14.3M -15.3% | $-12.4M -109.3% | $-5.9M |
| Operating Income | $-18.0M +19.1% | $-22.2M -24.3% | $-17.9M -23.9% | $-14.4M -14.6% | $-12.6M | — |
| EPS (Diluted) | $-1.57 +18.7% | $-1.93 -31.3% | $-1.47 -12.2% | $-1.31 | — | — |
| Total Assets | $11.0M -56.8% | $25.6M -41.4% | $43.6M -25.8% | $58.8M -20.4% | $74.0M +263.2% | $20.4M |
| Operating Cash Flow | $-15.7M +12.0% | $-17.8M -24.2% | $-14.3M -12.4% | $-12.8M -20.5% | $-10.6M -87.4% | $-5.7M |
| Free Cash Flow | $-15.7M +12.0% | $-17.8M -24.1% | $-14.4M -12.3% | $-12.8M -20.6% | $-10.6M | — |
Get alerted when LTRN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Lantern Pharma Inc. including:
Top Institutional Holders of LTRN
Empery Asset Management, LP
$3.5M842,669 shCM Management, LLC
$2.1M500,000 shVANGUARD CAPITAL MANAGEMENT LLC
$1.8M425,118 shRENAISSANCE TECHNOLOGIES LLC
$1.2M291,039 shBIOS Capital Management, LP
$1.0M249,397 shGEODE CAPITAL MANAGEMENT, LLC
$428.9K102,819 shVANGUARD FIDUCIARY TRUST CO
$208.3K49,950 shCITADEL ADVISORS LLC
$199.7K47,895 shWestside Investment Management, Inc.
$199.5K47,850 shQuadrature Capital Ltd
$165.1K39,593 sh
| Fund | Value | Shares |
|---|---|---|
| Empery Asset Management, LP | $3.5M | 842,669 |
| CM Management, LLC | $2.1M | 500,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.8M | 425,118 |
| RENAISSANCE TECHNOLOGIES LLC | $1.2M | 291,039 |
| BIOS Capital Management, LP | $1.0M | 249,397 |
| GEODE CAPITAL MANAGEMENT, LLC | $428.9K | 102,819 |
| VANGUARD FIDUCIARY TRUST CO | $208.3K | 49,950 |
| CITADEL ADVISORS LLC | $199.7K | 47,895 |
| Westside Investment Management, Inc. | $199.5K | 47,850 |
| Quadrature Capital Ltd | $165.1K | 39,593 |
More Healthcare Companies
View all Healthcare →Put LTRN on your watchlist
Track score changes the day Lantern Pharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LTRN a good stock to buy?
13F Pro's AI-powered analysis of Lantern Pharma Inc. (LTRN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LTRN are available on the LTRN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LTRN is classified as a small company.
Which hedge funds own LTRN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LTRN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lantern Pharma Inc.'s investment landscape.